Body fat & visceral fat estimator
Visceral fat — the fat stored around your internal organs — is one of the most clinically significant risk factors for insulin resistance, metabolic disease, heart disease and type 2 diabetes. This tool uses your waist circumference, hip circumference, height, weight, sex and age to estimate body fat percentage (using the Deurenberg formula), waist-to-hip ratio (WHR), waist-to-height ratio (WHtR), and a composite visceral fat risk level based on WHO clinical thresholds. Results are estimates only — see the accuracy disclaimer at the bottom of the calculator.
Body composition estimator
Estimate your body fat and visceral fat risk
Enter your measurements below to estimate body fat percentage, waist-to-hip ratio and visceral fat risk level. All results update live as you adjust the sliders.
Biological sexVisceral Fat Risk Level
Composite score: waist, WHR, WHtR & age
Based on WHO thresholds for waist circumference and waist-to-hip ratio.
Estimated Body Fat %
Deurenberg BMI-based formula (1991)
Ranges: Athletic <14% (W) / <6% (M), Fit, Average, High.
Waist-to-Hip Ratio (WHR)
WHO central adiposity indicator
WHO low risk: men <0.90, women <0.80.
BMI & Waist-to-Height
Supplementary size indicators
BMI
Overweight
Waist / Height
Elevated
What these measurements mean for your health
What is visceral fat?
Visceral fat is stored deep inside the abdomen, surrounding organs like the liver, pancreas and intestines. Unlike subcutaneous fat — the fat you can feel under the skin — visceral fat is metabolically active. It releases inflammatory cytokines and free fatty acids directly into the portal circulation, driving insulin resistance, type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease. You cannot feel or see visceral fat — waist measurements are the most accessible clinical proxy. [4]
Why WHR and WHtR matter
Waist-to-Hip Ratio (WHR) and Waist-to-Height Ratio (WHtR) are stronger predictors of cardiometabolic risk than BMI alone because they reflect fat distribution rather than just total body mass. A WHtR above 0.5 indicates elevated abdominal adiposity regardless of sex or ethnicity [3]. The WHO classifies WHR above 0.90 in men and above 0.80 in women as high risk [2].
GLP-1 therapy and body composition
GLP-1 medications such as Mounjaro (tirzepatide) and Wegovy (semaglutide) significantly reduce visceral fat — often more than total body weight reduction suggests. The SURMOUNT-1 trial showed tirzepatide produced mean waist circumference reductions of 14–18 cm at the highest dose [5]. Combined with Karespot dietician support, patients preserve lean muscle while losing predominantly visceral fat.
Frequently asked questions
Visceral fat is more dangerous than subcutaneous fat because it is metabolically active and located adjacent to vital organs. Subcutaneous fat is the fat you can feel under the skin — it is largely cosmetic and poses limited metabolic risk. Visceral fat, by contrast, is stored deep inside the abdomen surrounding the liver, pancreas and intestines. It releases inflammatory cytokines and free fatty acids directly into the portal circulation [4], increasing the risk of insulin resistance, type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease, and some cancers. This is why waist circumference is a stronger predictor of health risk than total body weight.
Accurate measurement technique is essential — small errors significantly affect WHR and WHtR results.
Waist circumference: Stand relaxed and breathe out normally. Place the tape measure horizontally around your abdomen at the level of your navel. The tape should be snug but not compressing the skin. Do not hold your breath or pull in your stomach.
Hip circumference: Place the tape at the widest point of your hips and buttocks, keeping it horizontal all the way around. Take the measurement without clothing where possible.
The WHO recommends standardised protocols for clinical measurement [2]. If you are unsure, your Karespot dietician can guide you during a consultation.
Yes — GLP-1 therapy reduces visceral fat disproportionately relative to total weight loss. The SURMOUNT-1 Phase 3 trial of tirzepatide (Mounjaro) demonstrated mean waist circumference reductions of 14–18 cm at the highest dose, alongside total body weight reduction of up to 22.5% [5]. This preferential reduction of central adiposity is one of the most clinically significant benefits of GLP-1 therapy, particularly for patients with metabolic syndrome, central obesity, or elevated cardiometabolic risk — regardless of overall BMI. Combined with structured dietician support, patients preserve lean muscle mass while losing predominantly visceral and abdominal fat.
Yes — for most people, WHR is a stronger predictor of cardiometabolic risk than BMI. BMI measures total body mass relative to height but cannot distinguish between fat mass and muscle mass, or between subcutaneous and visceral fat. Two people can have identical BMIs but very different health risks depending on where their fat is distributed.
The INTERHEART study of 27,000 participants across 52 countries found that WHR was a significantly stronger predictor of myocardial infarction risk than BMI across all ethnic groups [6]. A systematic review of 31 studies confirmed that WHtR above 0.5 outperformed both BMI and waist circumference for identifying cardiometabolic risk factors [3]. For Indians specifically, fat distribution risk occurs at lower BMI thresholds than Western populations.
This calculator uses the Deurenberg formula [1], a population-level estimate derived from BMI, age and sex. It cannot account for individual variation in body composition such as muscle mass, bone density, or fat distribution patterns.
The formula is known to be less accurate for:
- South Asian populations — Indians accumulate visceral fat at lower BMI levels than Western populations [7], meaning this tool may underestimate cardiometabolic risk for Indian users
- Athletes and people with high muscle mass — the formula will overestimate body fat percentage
- Older adults — body fat tends to be underestimated
- Pregnant women — results are not clinically applicable
For clinically accurate body fat measurement, methods such as DEXA scanning, bioelectrical impedance analysis (BIA), or hydrostatic weighing are required. Use this tool as a directional guide only — your Karespot doctor can arrange a proper clinical assessment.
Get a proper body composition assessment with Karespot
Your Karespot doctor can arrange a clinical assessment and interpret your body composition in the context of your overall metabolic health. Your registered dietician will then build a nutrition plan designed to reduce visceral fat, protect lean muscle mass, and support long-term GLP-1 treatment outcomes.
Clinical & Scientific References
- 1 Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: age- and sex-specific prediction formulas. Br J Nutr. 1991;65(2):105–114. PubMed ↗ — Original derivation and validation of the formula used in this calculator to estimate body fat percentage from BMI, age and sex.
- 2 World Health Organization. Waist circumference and waist–hip ratio: report of a WHO expert consultation. Geneva: WHO; 2008. WHO ↗ — Authoritative reference for WHR risk thresholds: >0.90 (men) and >0.80 (women) classified as high cardiometabolic risk.
- 3 Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. Obes Rev. 2012;13(3):275–286. PubMed ↗ — Meta-analysis of 31 studies establishing WHtR >0.5 as a stronger predictor of cardiometabolic risk than BMI or waist circumference alone.
- 4 Després JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012;126(10):1301–1313. PubMed ↗ — Comprehensive review of visceral adiposity as a metabolically active tissue releasing inflammatory cytokines and free fatty acids, driving insulin resistance and CVD risk.
- 5 Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216. SURMOUNT-1 ↗ — Phase 3 RCT showing tirzepatide produced mean body weight reduction up to 22.5% with significant reductions in waist circumference and visceral fat area.
- 6 Yusuf S, Hawken S, Ôunpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366(9497):1640–1649. PubMed ↗ — INTERHEART study demonstrating WHR is a stronger predictor of myocardial infarction risk than BMI across diverse ethnic populations.
- 7 Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab. 2008;93(11 Suppl 1):S9–30. PubMed ↗ — Evidence that South Asian populations accumulate visceral fat at lower BMI levels than Western populations; standard formulas may underestimate cardiometabolic risk in Indians.